Table 3. Demographic and clinical characteristics of individuals with a laboratory-confirmed EV-D68 infection, eight European countries, 1 September–14 October 2021 (n = 139).
| Number of cases | Proportion of cases | |
|---|---|---|
| Age group | ||
| 0–3 months | 7 | 5% |
| 4–12 months | 15 | 11% |
| 13–24 months | 22 | 16% |
| 2–5 years | 76 | 55% |
| 6–15 years | 9 | 6% |
| 16–25 years | 2 | 1% |
| 26–45 years | 2 | 1% |
| > 45 years | 6 | 4% |
| Sex | ||
| Female | 51 | 37% |
| Male | 88 | 63% |
| Symptoms (data reported for) | ||
| Any symptom reported (n = 121) | 120 | 99% |
| Fever (n = 111) | 49 | 44% |
| Enteric symptoms (n = 120) | 4 | 3% |
| Respiratory symptoms (n = 120) | 116 | 97% |
| Neurological symptomsa (n = 111) | 5 | 5% |
| Clinical information (data reported for) | ||
| Hospitalised (n = 49) | 30 | |
| Pre-existing conditionb (n = 45) | 20 | |
| Co-infections (data reported for) | ||
| Any co-infection reported (n = 43) | 16 | |
| Adenovirus | 4 | |
| Rhinovirus | 6 | |
| Human metapneumovirus | 1 | |
| Adenovirus and rhinovirus | 1 | |
| Adenovirus and bocavirus | 1 | |
| Rhinovirus and SARS-CoV-2 | 1 | |
| PIV4 and CMV | 1 | |
| Rhinovirus, bocavirus and PIV3 | 1 | |
CMV: cytomegalovirus; EV: enterovirus; PIV: parainfluenza virus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Reported neurological symptoms included headache, dizziness and agitation.
b Reported pre-existing conditions were asthma, chronic obstructive pulmonary disease, sleep apnoea and immunosuppression.